NCT05505877 2022-08-18
Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
Shanghai Gopherwood Biotech Co., Ltd.
Phase 1/2 Unknown
Shanghai Gopherwood Biotech Co., Ltd.
ChineseAMS
Tianjin Medical University Cancer Institute and Hospital